Rational development of lymph node-targeted lipid nanoparticles for immune-cell-oriented RNA, antigen, and therapeutic payload delivery.
Lymph node-targeted LNP development focuses on engineering lipid nanoparticle systems that can drain efficiently from local tissue, accumulate in draining lymph nodes, interact with antigen-presenting cells, and release payloads with measurable biological activity. For pharmaceutical and biotechnology teams working on mRNA, siRNA, antigen, peptide, protein, or immunomodulatory payloads, the major challenge is not simply making stable particles, but building a formulation that balances lymphatic transport, cellular uptake, endosomal escape, payload protection, and controlled biodistribution within one coherent design framework. BOC Sciences provides specialized targeted LNP development services to support research-stage formulation screening, lymph node-directed design, performance evaluation, and iterative optimization for advanced drug delivery programs.
Lymph node-targeted LNP development requires a compartment-aware design strategy. Instead of treating the lymph node as a single homogeneous target, BOC Sciences develops LNP systems according to the transport barriers, immune-cell composition, and biological functions of different lymph node substructures, including the afferent lymphatic entry region, subcapsular sinus, B cell follicles, paracortex, medulla, and lymph node homing interfaces. This approach helps researchers match LNP composition, surface modification, payload format, and evaluation methods with the intended lymph node microenvironment.
The afferent lymphatic entry region and subcapsular sinus are among the first lymph node interfaces encountered by locally administered nanoparticles. This strategy is particularly suitable for LNP programs that require efficient drainage from peripheral tissue to draining lymph nodes, such as RNA vaccines, antigen delivery systems, immune-modulating payloads, and reporter LNPs for lymph node distribution studies.
Subcapsular sinus macrophages play an important role in capturing lymph-borne particles and presenting particulate material to other immune-cell populations. This targeting direction is valuable for LNP programs focused on macrophage-associated antigen capture, immune modulation, particulate payload handling, and improved understanding of early lymph node immune-cell interactions.
B cell follicles and germinal center-related regions are important lymph node compartments for antigen recognition and B cell-associated immune responses. This development direction is suitable for antigen-displaying LNPs, B cell-interactive delivery systems, protein or peptide antigen formulations, and RNA-based platforms designed to influence B cell-associated immune readouts.
The paracortex is enriched in T cell-zone immune interactions and dendritic cell activity, making it a key compartment for RNA, antigen, and immune-modulating LNP systems. This strategy is especially relevant for mRNA LNPs, antigen-encoding RNA LNPs, dendritic cell-targeted payloads, and formulations requiring efficient cellular uptake and endosomal release in antigen-presenting cells.
The medullary region contains macrophage-rich sinus structures involved in lymph filtration and particulate material handling. This compartment-oriented strategy is suitable for LNP programs targeting macrophage-rich lymph node regions, immune-modulating small molecules, nucleic acid payloads, protein or peptide cargos, and labeled LNPs for cell-association mapping.
Homing receptor-mediated strategies use biological recognition mechanisms associated with immune-cell trafficking, lymphoid tissue localization, and lymph node retention. This approach is useful for LNP programs that aim to improve lymph node residence, immune-cell-associated transport, receptor-guided uptake, or ex vivo immune-cell loading for lymph node homing research models.
Lymph node-targeted LNP development requires more than passive lymphatic drainage. To achieve selective interaction with immune-cell populations inside draining lymph nodes, BOC Sciences designs targeting strategies around receptor biology, ligand accessibility, cellular uptake mechanisms, intracellular trafficking, and payload activity. Our approach supports researchers developing LNP systems for dendritic cell engagement, B-cell delivery, macrophage subset modulation, and homing receptor-mediated lymph node localization.
Dendritic cells are key antigen-presenting cells in lymph nodes, making them an important target for RNA, antigen, and immune-modulating LNP systems. BOC Sciences supports ligand-guided LNP design to enhance dendritic cell recognition while maintaining particle stability and intracellular delivery efficiency.
B cells are abundant in lymphoid tissues and can be relevant targets for antigen display, immune programming, antibody-response studies, and nucleic acid delivery research. We design B cell-oriented LNP systems by balancing receptor engagement, particle size, surface chemistry, and payload release behavior.
Lymph node macrophages include distinct functional subsets with different locations, scavenging behaviors, receptor profiles, and uptake capacities. BOC Sciences develops LNP strategies that distinguish productive macrophage targeting from nonspecific particle clearance.
Homing receptor-mediated targeting uses biological recognition mechanisms involved in lymphocyte trafficking and lymph node localization. This strategy is useful when the objective is to improve LNP interaction with lymph node-resident cells or cells migrating toward lymphoid tissue.
Work with BOC Sciences to design, screen, and optimize lymph node-targeted LNP formulations for RNA, antigen, and immune-cell-oriented delivery research.
The administration route strongly influences lymphatic drainage, lymph node exposure, immune-cell accessibility, and non-target tissue distribution of LNP systems. BOC Sciences supports the development of lymph node-targeted LNP formulations in multiple dosage formats, helping researchers match particle design with route-specific biological barriers, local tissue retention, payload stability, and target lymph node basin requirements.
| Dosage Format | Corresponding Administration Route | Applicable Payloads |
|---|---|---|
| Aqueous LNP Suspension | Intradermal, subcutaneous, intramuscular, or direct lymph node-related local administration in research models. | Suitable for mRNA, siRNA, ASO, saRNA, circRNA, miRNA, peptide antigens, protein antigens, immune-modulating small molecules, and reporter payloads that require flexible formulation screening and rapid route comparison. |
| Lyophilized LNP Powder for Reconstitution | Reconstituted before intradermal, subcutaneous, or intramuscular administration. | Applicable to RNA payloads, peptide/protein antigens, nucleic acid-ligand complexes, and stability-sensitive LNP systems that require improved storage handling, particle recovery, and post-reconstitution payload retention. |
| Hydrogel-Embedded LNP Formulation | Local subcutaneous or intradermal depot-style administration. | Suitable for mRNA, antigen-encoding RNA, protein antigens, peptide antigens, immune modulators, and co-delivery payloads where prolonged local exposure and gradual lymphatic access are desired. |
| Injectable Depot LNP Formulation | Subcutaneous or intramuscular local administration. | Applicable to RNA payloads, antigen payloads, immunomodulatory small molecules, adjuvant-like molecular cargos, and combination payloads that benefit from sustained local release and extended interaction with draining lymph node pathways. |
| Microneedle-Compatible LNP Formulation | Intradermal delivery through coated, dissolving, or hydrogel-assisted microneedle platforms. | Suitable for mRNA, saRNA, peptide antigens, protein antigens, immune-modulating cargos, and fluorescent or reporter-labeled LNPs designed for skin-associated lymphatic drainage studies. |
| Mucosal LNP Formulation | Intranasal or other mucosal administration routes in suitable research settings. | Applicable to mRNA, siRNA, antigen-encoding RNA, peptide/protein antigens, mucosal immune-modulating molecules, and labeled LNP systems intended for interaction with mucosa-associated lymphoid tissues. |
| Targeted Immune-Cell Loading Format | Ex vivo immune-cell incubation followed by cell-based lymph node homing research models. | Suitable for siRNA, mRNA, ASO, reporter RNA, immune-modulating payloads, and labeled LNPs designed for controlled loading into dendritic cells, macrophages, B cells, or other immune-cell populations. |
| Imageable or Reporter-Labeled LNP Format | Route-matched administration for lymph node distribution, cellular uptake, and in vivo tracking studies. | Applicable to fluorescent lipid-labeled LNPs, luminescent reporter systems, dye-loaded LNPs, radiolabel-compatible research formulations, reporter mRNA LNPs, and dual-labeled systems for tracking lymph node localization and cell association. |
For each administration route, BOC Sciences evaluates whether the selected dosage format is compatible with the intended payload type, including nucleic acids, antigens, proteins, peptides, small molecules, immune-modulating cargos, and reporter labels. This route-aware development approach helps researchers determine whether limited lymph node exposure is caused by the LNP composition, the dosage format, payload instability, or the delivery route.
Lymph node-targeted LNP programs often fail because the formulation is optimized for one metric while overlooking transport, uptake, release, or payload stability. We help clients diagnose these bottlenecks and convert scattered data into actionable formulation decisions.
✔ Poor Lymphatic Drainage
Oversized, aggregated, or strongly adhesive particles may remain near the administration site instead of reaching draining lymph nodes. We tune size, PEG-lipid content, ionic conditions, and surface hydration to improve drainage behavior.
✔ High Off-Target Organ Signal
Some LNPs show strong non-target tissue distribution that masks lymph node activity. We use composition screening, surface modulation, and nanoparticle in vivo distribution analysis to identify candidates with improved lymph node-to-non-target profiles.
✔ APC Uptake Without Functional Expression
High uptake does not always translate into strong payload activity. We investigate whether the limiting factor is endosomal trapping, lipid composition, payload release, or intracellular degradation.
✔ Ligand-Induced Aggregation
Dense surface ligands may improve receptor binding but destabilize the LNP or increase nonspecific phagocytic uptake. We optimize ligand density, PEG spacer design, and conjugation strategy to balance specificity and colloidal stability.
✔ Encapsulation Loss During Optimization
Formulation changes that improve lymphatic movement can reduce RNA or antigen loading. We use parallel encapsulation, recovery, and stability measurements to prevent performance gains from being offset by payload loss.
✔ Unclear Cause of Weak Biological Readout
Weak reporter expression or limited immune-cell activity may result from poor drainage, low uptake, insufficient endosomal escape, payload instability, or cell-type mismatch. We separate these variables through staged analytical and functional studies.
We review the payload type, intended lymph node-related model, target immune-cell population, expected readouts, and formulation constraints to define a practical development strategy.
Focused LNP libraries are prepared by varying ionizable lipid ratio, helper lipid composition, PEG-lipid content, ligand density, payload ratio, and microfluidic mixing parameters.
Candidate formulations are assessed for particle size, PDI, zeta potential, morphology, encapsulation, storage behavior, serum stability, cellular uptake, and reporter or payload activity using lipid nanoparticle characterization workflows.
We integrate physicochemical, uptake, expression, and biodistribution data to rank formulation candidates, identify design bottlenecks, and recommend the next optimization cycle.
Challenge: A biotechnology research team developed an mRNA antigen LNP for draining lymph node delivery, but the first formulation showed a strong local depot signal and inconsistent reporter expression in lymph node tissue. The initial particles were approximately 135-160 nm with a broad size distribution, and the PEG-lipid level was selected mainly for colloidal stability rather than lymphatic movement.
Diagnosis: BOC Sciences compared particle size, PDI, encapsulation, serum stability, and small-animal imaging data across the client's starting formulation. The data suggested that excessive particle size and slow PEG-lipid deshielding limited lymphatic access, while the ionizable lipid ratio was sufficient for RNA encapsulation but not ideal for downstream expression.
Solution: We constructed a 16-formulation screening matrix that varied PEG-lipid content from low to moderate levels, adjusted the ionizable/helper lipid balance, and modified microfluidic total flow rate and flow rate ratio to generate particles in the 75-115 nm range. Three candidate formulations were advanced into cellular uptake and reporter-expression assays, followed by in vivo imaging comparison of injection site, draining lymph node, liver, and spleen signal.
Result: The selected formulation achieved a narrower PDI below 0.15, maintained high RNA encapsulation, and showed an approximately 2.8-fold higher draining lymph node-to-liver reporter signal ratio than the starting formulation in the exploratory imaging screen. The client received a ranked formulation map showing which lipid and process variables most strongly influenced lymph node-directed performance.
Challenge: A drug discovery group needed a lymph node-oriented siRNA LNP with enhanced dendritic cell interaction. Their ligand-decorated prototype showed increased total immune-cell uptake, but flow-based cellular analysis revealed substantial macrophage-associated signal and reduced siRNA activity in dendritic cell models.
Diagnosis: The initial mannose-lipid density increased receptor engagement but also introduced surface heterogeneity and aggregation in protein-containing medium. The formulation had a PDI above 0.22 after serum exposure, indicating that the ligand layer and PEG-lipid architecture were not well balanced.
Solution: BOC Sciences screened mannose-lipid density, PEG spacer length, ionizable lipid ratio, and N/P ratio across a focused design space. Candidate LNPs were evaluated for size stability, siRNA encapsulation, dendritic cell uptake, macrophage uptake, lysosomal colocalization, and gene-silencing readout in an immune-cell-relevant in vitro model. The best-performing design used a moderate ligand density rather than the highest ligand density, preserving receptor interaction while reducing nonspecific aggregation.
Result: The optimized LNP maintained PDI below 0.16 in protein-containing medium, preserved strong siRNA encapsulation, improved dendritic cell-associated uptake compared with the non-ligand control, and produced a clearer gene-silencing response. The client used the formulation map to prioritize a smaller number of LNP candidates for downstream lymph node distribution studies.
Integrated Targeting LogicWe connect lymphatic transport, immune-cell interaction, intracellular release, and payload activity rather than optimizing particle size or encapsulation as isolated metrics.
Payload-Flexible Formulation ExperienceOur LNP workflows support RNA, antigen, peptide, protein, small-molecule, and co-delivery concepts, with design decisions adapted to molecular properties and biological readouts.
Quantitative CharacterizationWe provide particle size, PDI, zeta potential, morphology, encapsulation, leakage, serum stability, uptake, and expression-related data to support evidence-based formulation ranking.
Formulation-Process ConnectionMicrofluidic preparation, mixing parameters, buffer exchange, and concentration steps are evaluated as part of the formulation design, helping clients identify more reproducible development conditions.
Biodistribution-Guided OptimizationCandidate selection is guided by how LNPs behave across injection site, draining lymph nodes, immune-cell compartments, and non-target tissues in appropriate research models.
Lymph node-targeted LNP development focuses on designing lipid nanoparticles that can deliver therapeutic or immunological payloads more efficiently to lymph node-associated tissues and immune cells. Unlike general LNP formulation work, this service requires careful control of particle size, lipid composition, surface properties, payload protection, and biological interaction after administration. For drug development teams, the goal is not only to produce stable nanoparticles, but also to understand whether the formulation supports lymphatic transport, local retention, cellular uptake, and functional payload release. BOC Sciences helps clients build a formulation strategy that links composition, physicochemical properties, and performance data, enabling more rational selection of candidate LNP systems for vaccines, nucleic acid delivery, and immune-modulating research applications.
Lymph node-targeted LNP delivery can be applied to a range of payloads, especially those intended to interact with immune cells or lymphoid tissues. Common examples include mRNA, siRNA, circRNA, oligonucleotides, antigen-encoding nucleic acids, immune-modulating molecules, peptides, proteins, and selected hydrophobic small molecules. Each payload type places different demands on the formulation. For example, mRNA requires protection from degradation and efficient cytosolic release, while siRNA often requires strong encapsulation and controlled intracellular availability. Small molecules may require lipid phase compatibility and controlled release behavior. BOC Sciences can support payload-specific LNP formulation screening by evaluating encapsulation, particle stability, leakage, cell uptake, and expression-related performance, helping clients identify formulations that are better aligned with their research objectives.
Lymph node-targeted LNP formulations are optimized through systematic screening rather than isolated adjustment of a single formulation parameter. Key variables often include ionizable lipid selection, helper lipid ratio, cholesterol content, PEG-lipid percentage, N/P ratio, buffer condition, mixing speed, total lipid concentration, and payload input level. These parameters influence particle size, PDI, surface charge, encapsulation efficiency, colloidal stability, and biological delivery behavior. A practical optimization workflow usually begins with a small formulation matrix, followed by physicochemical characterization and functional comparison in relevant cell models. BOC Sciences can help clients refine candidate formulations step by step, eliminating unstable or poorly loaded systems early and prioritizing LNPs that show stronger payload protection, better immune cell interaction, and more suitable lymph node-related distribution potential.
Evaluating lymph node LNP performance requires more than a single fluorescence image or one encapsulation result. A reliable data package usually includes particle size distribution, PDI, zeta potential, morphology, encapsulation efficiency, payload integrity, serum stability, leakage behavior, cell uptake, intracellular release, and functional readout such as protein expression or target silencing. For immune-focused delivery projects, it is also important to assess how different immune cell populations interact with the LNP, because particle accumulation near lymphoid tissue does not automatically mean efficient delivery into the intended cell type. BOC Sciences supports integrated evaluation strategies that connect formulation attributes with biological performance, allowing clients to compare candidates based on interpretable data rather than relying on isolated or misleading endpoints.
Lymph node-targeted LNP delivery can be designed through both passive lymphatic transport and active immune-cell targeting. Passive targeting mainly depends on particle size, surface charge, deformability, PEG-lipid structure, and lipid composition, which influence whether LNPs drain from the injection site into lymphatic vessels and accumulate in lymph nodes. Active targeting may involve surface ligands such as mannose, peptides, antibodies, or other receptor-recognition motifs to enhance uptake by dendritic cells, macrophages, or antigen-presenting cells within lymphoid tissues. For development projects, the targeting strategy should not be evaluated by biodistribution alone; it should also be linked with particle stability, encapsulation efficiency, cell-specific uptake, payload expression, and immune-cell interaction to identify a formulation with practical delivery value.
